Trial Profile
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs SEL 212 (Primary) ; Pegloticase
- Indications Gout; Gouty arthritis
- Focus Therapeutic Use
- Acronyms COMPARE
- Sponsors Selecta Biosciences
- 14 Jul 2023 Results published in the Rheumatology
- 30 Sep 2020 According to a Selecta Biosciences media release, the company will held a conference call on 30th September to discuss the COMPARE study.
- 30 Sep 2020 According to a Selecta Biosciences media release, a full analysis of safety signals, including gout flare incidence and severity, awaits evaluation of the full data set and will be reported together with the full efficacy analysis at a later medical meeting.